Cytori’s business is focused on the development of therapies in multiple fields using Adipose Derived Regenerative Cells. The company has developed technology that automates the processing of ADRC’s
Cytori’s goal is to provide real-time, POC, Autologous Cell Therapy in which a patient’s tissue is harvested, processed and delivered back to the same patient at the bedside within approximately an hour and a half.
Our current generation product, the Celution 800 provides real time – point of care access to ADRC’s. The system standardizes the extraction, washing, and concentrating of ADRC’s for present or future clinical use.
The current generation product is CE Marked and has been commercially available since 2008. The current system is approved for Breast Reconstruction, Breast Assymmetry, Soft Tissue Wasting and Crohn’s Fistula.Something to note is that the current (device and consumable) is manufactured in San Diego. This vertical integration approach has served us well but we realized a more optimal platform was required for the Hospital market.
In 2005, we found an outstanding partner in Olympus corporation and a joint venture was formed. OLY & CYTX have co-developed the next generation platform called the Celution One. OLY will mass manufacture the device and consumable OUS.
Celution One is a hospital based system intended for use in the O.R. and Cath Lab. It is an automated closed system that intra-operatively process the tissue/cells in real time. The unit has onboard liposuction system and as well as significantly improved Ergonomic features such barcode scanning for the consumable and an multilingual interactive display.
Compared to current generation – i.e. shorter processing times, handle large tissue volumes
CYTX 6th International Conference on Cell Therapy for Cardiovascular Disease Presentation
Celution One: Next Generation Innovation <br />Brad Conlan <br />Director, Regenerative Medicine <br />Business Unit<br />
Safe Harbor Statement<br />This presentation may contain certain ‘forward-looking statements’. All<br />statements other statements, than statements of historical fact, that address activities, events or developments that we intend, expect, project,<br />believe or anticipate will or may occur in the future are forward-looking<br />statements. Such statements are based upon certain assumptions and<br />assessments made by our management in light of their experience and<br />their perception of historical trends, current conditions, expected future<br />developments and other factors they believe to be appropriate.<br />The forward-looking statements included in this presentation are also<br />subject to a number of material risks and uncertainties. We caution<br />investors not to place undue reliance on the forward-looking statements<br />contained in this presentation. We would advise reading our annual report filed with the United States Securities and Exchange Commission on Form 10-K for a more detailed description of these risks.<br />
……..</li></li></ul><li>Separate,<br />process <br />and deliver<br />1.5 hours<br />Return cells/tissue <br />to same patient<br />Real-Time, Point-of-Care Autologous Cell Therapy <br />Present – Celution Clinical Relevance<br />Harvest donor <br />tissue<br />Harvest tissue and return to <br />patient in same procedure<br />
Present – Celution Product Generations<br />For Delivery of ADRCs<br />Real-time, point-of-care access to adult adipose-derived stem and regenerative cells (ADRCs)<br />Standardizes the extraction, washing and concentration of ADRCs for present or future clinical use.<br />Celution® 805/CRS <br />Consumable Set<br />Celase™ 835 / CRS Reagent<br />Celution ® 800/CRS Device<br />*Currently not available in the United States<br />
Present – Celution Clinical Relevance<br />• CE marked<br />• Clinical Applications<br /> Breast Reconstruction<br /> Breast Asymmetry<br /> Soft Tissue Wasting<br /> Crohn’s Fistula<br />Celution ® 800/CRS Device<br />*Currently not available in the United States<br />